Clinical trials: Influenza Viruses
Influenza
Evaluate Safety & Immunogenicity of a Pandemic Influenza Vaccine (GSK1562902A) in Children
The present study is designed to evaluate in children (aged between 3 and 9 years) the immunogenicity and safety of different antigen doses of the candidate vaccine (GSK1562902A) administered following a two-administration…
- Trial name
- NCT00502593
- Testing
- Pandemic Influenza Vaccine (GSK1562902A), Fluarix™
- Where
- 7 sites in Spain
- Volunteers
- 138 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Study to Evaluate the Immunogenicity and Safety of 'IL-YANG Quadrivalent Influenza Vaccine Inj.'
This study evaluates the immunogenicity and safety of 'IL-YANG Quadrivalent Influenza Vaccine Inj.' in healthy male and female adults at the age of 19 or older.
- Trial name
- NCT02677493
- Testing
- IL-YANG Quadrivalent Influenza Vaccine, IL-YANG Flu Vaccine Prefilled Syringe, IL-YANG Trivalent Influenza Vaccine
- Volunteers
- 1,794 people, healthy volunteers welcome
- Sponsor
- Il-Yang Pharm. Co., Ltd.
Influenza
A Multicenter, Double-blind, Parallel Phase III Study
A Multicenter, Randomized, Double-blind, Active-controlled, Parallel Phase III
- Trial name
- NCT02352584
- Testing
- GC3110A(Quadrivalent), GC Flu(Trivalent), GC3110A(Trivalent)
- Where
- South Korea
- Volunteers
- 1,299 people, healthy volunteers welcome
- Sponsor
- Green Cross Corporation
Influenza
Postmarketing Surveillance Study for Quadrivalent Influenza Vaccine (VaxigripTetra®) in Subjects Aged 6 to 35 Months
Multi-center, observational, active safety surveillance study in participants aged 6 to 35 months in Korea under routine clinical practices.
- Trial name
- NCT05832333
- Testing
- VaxigripTetra®
- Where
- 12 sites in South Korea
- Volunteers
- 682 people, healthy volunteers welcome
- Sponsor
- Sanofi
covid19 Infection, Influenza, Human
Covid-19 and Influenza Oral Vaccine Study
The purpose of the current study is to assess the effectiveness of protein-based COVID-19 or influenza vaccines when given individually or together via oral/ sublingual mucosal route instead of intramuscular delivery.
- Trial name
- NCT06355232
- Testing
- Covid-19 vaccine, Influenza vaccine
- Where
- Australia
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Vaxine Pty Ltd
Influenza, Human
Evaluation of a Recombinant Quadrivalent Influenza Vaccine Versus a Marketed Quadrivalent Inactivated Influenza Vaccine in Children 3 to 17.
Multicentric study, Phase III; this study is a randomized, participant- and observer-blind, parallel group evaluation to evaluate the immunogenicity, relative efficacy, safety and reactogenicity of a recombinant quadrivalent…
- Trial name
- NCT03460743
- Testing
- Study group - quadrivalent recombinant hemagglutinin influenza vaccine, Control group - quadrivalent inactivated influenza vaccine
- Where
- 11 sites in Mexico
- Volunteers
- 1,556 people, healthy volunteers welcome
- Sponsor
- Laboratorios Liomont
Influenza
A Pivotal Trial to Assess the Safety and Clinical Efficacy of the M-001 as a Standalone Universal Flu Vaccine
The pivotal Phase 3 trial plans to enroll a total of approximately 12,460 participants aged 50+ over two years. Participants will be immunized twice with the M-001 universal influenza vaccine candidate or placebo and then…
- Trial name
- NCT03450915
- Testing
- M-001, Saline
- Where
- 2 sites in Poland
- Volunteers
- 12,460 people, healthy volunteers welcome
- Sponsor
- BiondVax Pharmaceuticals ltd.
Influenza, Pandemic Influenza
A/H1N1 Immunogenicity and Safety in Infants, Children and Adolescents
The purpose of this study is to determine the preferred dose of H1N1 pandemic influenza vaccine in a pediatric population, aged 6 months to 17 years, based upon assessments of immunogenicity and safety.
- Trial name
- NCT00976469
- Testing
- H1N1 pandemic influenza vaccine (whole virion, Vero cell-derived, inactivated), Seasonal trivalent influenza vaccine (licensed) for the season 2010/2011
- Where
- 6 sites in Austria, Germany
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Alachua Government Services, Inc.
Influenza
Study to Evaluate the Safety and Immunogenicity of KBP-V001 Quadrivalent Influenza Vaccine in Healthy Adults
This is an observer-blinded, randomized, placebo-controlled, parallel group study to evaluate safety and immunogenicity of TAP-V001 quadrivalent influenza vaccine in healthy adult subjects.
- Trial name
- NCT04439695
- Testing
- Low dose, Intermediate dose, High dose
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- KBio Inc
Influenza
Efficacy Study of an Investigational Influenza Vaccine (Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection (CCII)
The primary purpose of this study is to demonstrate the efficacy of an investigational Vero-cell derived influenza vaccine to prevent infection in an adult population with an influenza virus that is antigenically similar to one…
- Trial name
- NCT00566345
- Testing
- Inactivated seasonal influenza vaccine (split virus, Vero cell-derived), Phosphate buffered saline
- Where
- 34 sites in United States
- Volunteers
- 3,670 people, healthy volunteers welcome
- Sponsor
- Alachua Government Services, Inc.
Influenza
Surveillance Study to Assess the Safety of Flublok Quadrivalent (Influenza Vaccine) in Pregnant Women and Their Offspring
Primary Objective: To evaluate the safety of Flublok Quadrivalent influenza vaccine in pregnant women included in the VAP00003 Study (NCT03694392) and their offspring exposed during pregnancy or up to 28 days preceding the…
- Trial name
- VAP00007 (NCT04460781)
- Testing
- Flublok Quadrivalent influenza vaccine RIV4, Standard-dose quadrivalent inactivated influenza vaccine SD-IIV4
- Where
- United States
- Volunteers
- 96,175 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza
Immunogenicity & Safety Study of Fluviral® (2010 - 2011 Season) in Adults Aged 18 to 60 Years and Over 60 Years
This study is designed to test the safety and immunogenicity of Fluviral® (2010 - 2011 Season) in adults aged 18 to 60 years and over 60 years.
- Trial name
- NCT01153685
- Testing
- Fluviral®
- Where
- Canada
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza Infection
A Phase 2, Double-blind Study to Evaluate Intranasal Trivalent Influenza Virus Vaccine in Healthy Adult
The objectives of this phase 2 study are to evaluate immunogenicity, safety and tolerability of AD07030, a trivalent influenza virus antigens vaccine, given intranasally in 2 doses in healthy adult volunteers.
- Trial name
- NCT03784885
- Testing
- AD07010, Inactivated trivalent influenza vaccine
- Where
- Taiwan
- Volunteers
- 345 people, healthy volunteers welcome
- Sponsor
- Advagene Biopharma Co. Ltd.
Influenza
Immunogenicity of GSK Biologicals' Pandemic Influenza Vaccine (GSK1562902A) at Different Boosting Vaccination Schedules
Today, the leading contender for the next influenza pandemic is H5N1, a strain of avian virus found primarily in domestic and wild birds. Experts warn that the next influenza pandemic is imminent and could be severe.
- Trial name
- NCT00652743
- Testing
- Pandemic influenza vaccine GSK1562902A
- Where
- 6 sites in Hong Kong, Singapore and 2 more
- Volunteers
- 845 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Trial to Assess the Shedding,Immunogenicity, and Safety of FluMist Administered to Healthy Individuals 5-49 Years of Age
To describe the proportion of individuals 5-49 years of age who shed vaccine strain viruses. To describe the duration of shedding of vaccine viruses in individuals 5-49 years of age.
- Trial name
- NCT00192140
- Testing
- FluMist
- Where
- 11 sites in United States
- Volunteers
- 345 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Pregnant Women, Influenza
Flucelvax Pregnancy Registry
The goal of the registry is to develop a better understanding of the safety of Flucelvax in women and their offspring who were exposed to the vaccine during pregnancy
- Trial name
- NCT02258178
- Testing
- Flucelvax (cTIV)
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Seqirus
Influenza
Study to Evaluate the Safety and Immune Response of Two-Doses of Candidate Influenza Vaccine GSK 1557484A in Adults
The purpose of this study is to evaluate the safety and immune response of two-doses of GSK Biologicals' candidate influenza vaccine GSK 1557484A with or without adjuvant in adults.
- Trial name
- NCT00510874
- Testing
- Pumarix™, Pandemrix ™
- Where
- 10 sites in United States, Canada
- Volunteers
- 780 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Immunogenicity and Safety of GSK Biologicals' (Pre-) Pandemic Influenza Candidate Vaccine
This trial will assess the immunogenicity and safety elicited by the adjuvanted GSK Biologicals' (pre-) pandemic influenza candidate vaccine in healthy Japanese adults.
- Trial name
- NCT00742885
- Testing
- Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted
- Where
- 2 sites in Japan
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Seasonal Influenza
A Study of mRNA-1020 and mRNA-1030 Seasonal Influenza Vaccines in Healthy Adults
The primary objective of this study is to evaluate the safety, reactogenicity, and humoral immunogenicity of mRNA-1020, mRNA-1030, and mRNA-1010 vaccines against vaccine-matched influenza A and B strains.
- Trial name
- NCT05333289
- Testing
- mRNA-1030, mRNA-1020, mRNA-1010
- Where
- 15 sites in United States
- Volunteers
- 572 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Healthy Volunteers, Influenza
Study to Assess Safety and Immunogenicity of an Egg-based H5N8 Influenza Vaccine at Multiple Dose Levels Adjuvanted With Matrix-M in Healthy Participants 18 Years of Age and Above.
The study aims to evaluate an egg-based H5N8 influenza vaccine up to 3 dose levels (low, medium, and high dose) given with or without adjuvant to see if the adjuvant improves vaccine effectiveness.
- Trial name
- NCT07779408
- Testing
- Flu H5 egg pandemic low dose vaccine, with adjuvant, Flu H5 Egg Pandemic medium dose vaccine, with adjuvant, Flu H5 Egg Pandemic high dose vaccine, with adjuvant
- Where
- 16 sites in United States
- Volunteers
- 640 people, healthy volunteers welcome
- Sponsor
- Sanofi
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.